Winning Pharmaceutical R&D Strategies: Boosting profitability through improvements in portfolio management, licensing and clinical trials
Executive Summary
Winning Pharmaceutical R&D Strategies: Boosting profitability through improvements in portfolio management, licensing and clinical trials, examines the core areas where companies can implement procedural enhancements to maximize their resources and eliminate inefficiencies in the R&D process. Conflict between the continued need to meet investors’ short-term growth expectations and longer term productivity problems has led to a substantial increase in R&D expenditure in a bid to maintain profit margins. However, pharmaceutical companies are experiencing diminishing returns on investment in their R&D pipelines. Factors greatly inhibiting the industry are the lack of genuine innovation and the lack of commitment to refining existing R&D processes with a view to generating greater efficiencies and substantial cost savings. Improving the productivity of each step of the R&D process can improve margins without related expansion of the R&D budget. Long-term, this is a more sustainable growth strategy than continued investment in current activities. Use this report to devise strategies to overcome inefficiencies in your R&D process and generate greater returns on investment.
